Key Points
- Director Nilda Mesa sold 258 shares of United Therapeutics on May 12 at an average price of $581.93, totaling about $150,138. After the sale, she still held 5,028 shares valued at roughly $2.93 million.
- United Therapeutics missed quarterly earnings estimates, reporting $5.82 EPS versus the expected $7.00, while revenue of $781.5 million also came in slightly below forecasts. Revenue was down 1.6% year over year.
- Wall Street remains broadly positive on UTHR, with 11 Buy ratings and 2 Hold ratings. The stock’s consensus target price is $619.42, and several analysts recently raised their price targets.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 258 shares of United Therapeutics stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the transaction, the director owned 5,028 shares of the company's stock, valued at approximately $2,925,944.04. The trade was a 4.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
United Therapeutics Price Performance
NASDAQ:UTHR opened at $579.54 on Thursday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market capitalization of $24.60 billion, a P/E ratio of 21.39, a P/E/G ratio of 1.84 and a beta of 0.60. The business has a 50 day simple moving average of $554.96 and a 200 day simple moving average of $505.54.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 EPS. The company's revenue for the quarter was down 1.6% compared to the same quarter last year. Research analysts anticipate that United Therapeutics Corporation will post 27.64 EPS for the current fiscal year.
Institutional Trading of United Therapeutics
Several hedge funds have recently added to or reduced their stakes in the business. Arjuna Capital raised its stake in United Therapeutics by 2.8% during the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company's stock valued at $393,000 after acquiring an additional 18 shares in the last quarter. Clearstead Advisors LLC raised its stake in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock worth $117,000 after buying an additional 23 shares in the last quarter. Sage Rhino Capital LLC raised its stake in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company's stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company's stock worth $276,000 after buying an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company's stock worth $392,000 after buying an additional 26 shares in the last quarter. Institutional investors own 94.08% of the company's stock.
Analysts Set New Price Targets
UTHR has been the subject of a number of analyst reports. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. TD Cowen lifted their target price on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research note on Monday, March 30th. HC Wainwright lifted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a "buy" rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Finally, Oppenheimer lifted their target price on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $619.42.
Read Our Latest Stock Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
